What Morepen Laboratories does

Morepen Laboratories Limited is an Indian pharmaceutical manufacturer founded in 1984 and headquartered in Gurgaon, with integrated manufacturing operations at Baddi and Masulakhanna in Himachal Pradesh across 10 purpose-built plants and capacity expanding toward 800 KL. The company operates in four business segments: (1) Active Pharmaceutical Ingredients (APIs), where it is the largest global producer of Montelukast at 45MT per annum and holds over 90% US market share of generic Loratadine at 120MT, with USFDA, WHO GMP, and EU GMP certified facilities supplying exports to over 80 countries; (2) Home Diagnostics, where it was the first company to manufacture glucometers and strips in India, with an installed base of approximately 4 million glucose monitors and 450 million strips sold; (3) Dr. Morepen branded OTC and consumer healthcare products, comprising 400+ SKUs including the 70-year-old Burnol and 40-year-old Lemolate brands, reaching over 100 million consumers; and (4) Finished Formulations spanning 150+ SKUs across cardiac, diabetic, and multispecialty categories. The company was carved out from a pure-play API exporter via a USD 100 million investment from Corinth Group of Switzerland in April 2021, a Rs 200 crore QIP in August 2024, the medical devices business carve-out into a wholly-owned subsidiary, and most recently a landmark Rs 825 crore (~USD 91 million) multi-year CDMO contract from a leading global pharma major that marks a strategic pivot from spot API supply toward long-term structured contract manufacturing programs. Its go-to-market combines direct enterprise sales for API and CDMO customers, a 2,000+ distributor domestic network for diagnostics and OTC products, and direct-to-consumer channels via the Dr. Morepen Pharmacy and Sync mobile applications.

Name

Morepen Laboratories

Legal name

Morepen Laboratories Limited

Website

https://morepen.com

Company type

Public

Founded year

1984

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Morepen Laboratories is an Indian pharmaceutical manufacturer producing APIs (Montelukast, Loratadine, Atorvastatin), home diagnostics, branded OTC products, and finished formulations, exporting to over 80 countries and serving 100+ million domestic consumers under the Dr. Morepen brand, with a recent pivot into CDMO services via a Rs 825 crore multi-year contract.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

akta.pro secondary industry

Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Active Pharmaceutical Ingredients
• Generic Drug Manufacturing
• Home Diagnostic Devices
• Contract Development Manufacturing
• OTC Healthcare Products

Headquarters

HQ city

Gurugram

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Active Pharmaceutical Ingredients (API): Bulk drug API production and export to regulated markets. The company is a global leader with USFDA-approved facilities. Key products include Montelukast, Loratadine, and Atorvastatin. Exports currently account for 70% of API business, expected to rise to 80% over three years.
2. Contract Development and Manufacturing (CDMO): Multi-year CDMO mandates from global pharma majors. Secured Rs 825 crore CDMO contract from leading global pharma company, expected to execute within 12-15 months. Represents strategic shift from spot business to long-term structured customer programmes.
3. Home Diagnostics: Self-care products including BP Monitors, Glucose Monitors, Nebulizers, Thermometers, weighing scales and steamers. Sales through large distribution network in India.
4. OTC & Healthcare Products: Over 400+ OTC products under Dr. Morepen brand including flagship products Burnol (70-year legacy, market leader) and Lemolate (40-year brand). Products available through pharmacy app and retail channels.
5. Finished Formulations: High quality generic medicines for multispecialty, cardiac and diabetic categories through dedicated business units having 150+ SKUs. Integrated manufacturing facilities for contract manufacturing requirements.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Morepen Laboratories manufactures and exports Active Pharmaceutical Ingredients (APIs) such as Montelukast, Loratadine, and Atorvastatin from USFDA-approved facilities. The company also produces home diagnostic devices (glucometers, BP monitors), over 400 OTC healthcare products under the Dr. Morepen and Gubb World brands, finished generic formulations, and offers Contract Development and Manufacturing (CDMO) services to global pharmaceutical companies.

Product overview

Morepen Laboratories is a diversified pharmaceutical company with four core business segments: Active Pharmaceutical Ingredients (APIs), Home Diagnostics, Dr. Morepen OTC products, and Finished Formulations. The company operates USFDA-approved manufacturing facilities and exports to over 80 countries. Its API division is a global leader in Montelukast and Loratadine production, while its consumer health division under Dr. Morepen and Gubb World brands serves over 100 million consumers with 400+ OTC products. The company has recently expanded into contract development and manufacturing (CDMO) services with a landmark ₹825 crore mandate, and into digital health with mobile applications for health monitoring and pharmacy services.

Differentiator

Problem solved

Functional benefit

Brands

• Burnol: Original Burns Cream with 70-year legacy, market leader in burn treatment category in India
• Lemolate
• LightLife
• Empamore
• Intelicaps

Products and services

• Active Pharmaceutical Ingredients (APIs) Bulk drug APIs production with USFDA-approved facilities. Key products include Montelukast (largest global producer, 45MT annual capacity), Loratadine (over 90% US market share, 120MT capacity), Atorvastatin (top manufacturer in blockbuster US$18bn market), and Fexofenadine Hydrochloride (USFDA-approved generic Allegra). Exported to over 80 countries with USFDA, WHO GMP, and EU GMP certifications.
• Home Diagnostics Self-care diagnostic products including Blood Glucose Monitors (4 million installed base, 450 million strips sold), BP Monitors, Nebulizers, Thermometers, weighing scales, and steamers. Marketed under Dr. Morepen brand with ISO-13485 certified manufacturing.
• Dr. Morepen OTC Healthcare Products Over 400 OTC products under Dr. Morepen brand including flagship Burnol (70-year-old burns cream and market leader), Lemolate (40-year cough & cold brand), and a wide range of healthcare, grooming, and wellness products serving over 100 million consumers.
• Finished Formulations High-quality generic medicines for multispecialty, cardiac, and diabetic categories through dedicated business units with 150+ SKUs. Integrated manufacturing facilities support contract manufacturing requirements for global customers.
• CDMO Services Contract Development and Manufacturing Organization services for global pharmaceutical majors, leveraging USFDA-approved facilities and integrated manufacturing infrastructure. Represents a strategic shift from spot business to structured long-term customer programmes.
• Empamore New pharmaceutical product for Type 2 Diabetes, heart failure, and kidney disease launched at 90% lower cost than existing options in the Indian market.
• LightLife by Dr. Morepen Weight management wellness product developed in partnership with OptiBiotix, providing a scientific approach to long-lasting weight management for Indian consumers.
• Intelicaps Probiotic Technology Proprietary Intelicaps technology for enhanced probiotic delivery, first time introduced in India. Used as a differentiated delivery platform for probiotic products.

Quantifiable outcome

• 69% year-on-year net profit increase to ₹20 crore in Q4 FY26
• +4 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and flagship.

• VIT BhopalcoreStrategic or Co-development Partner · 1 June 2026Dr. Morepen partnered with VIT Bhopal to establish a modern health centre for 17,000+ students and faculty, providing healthcare services and products to the university community.
• Leading Global Pharma Major (CDMO)flagshipStrategic or Co-development Partner · 23 February 2026Rs 825 crore multi-year CDMO contract - one of the largest in company's history. Strategic shift from spot business to long-term structured customer programmes. Supplies expected to begin within 4-5 months.
• OptiBiotixcoreStrategic or Co-development Partner · 20 March 2024Dr. Morepen partnered with OptiBiotix to deliver safe, science-backed weight management solution to India. Launched LightLife wellness product for weight management.
• Russian Direct Investment Fund (RDIF)coreStrategic or Co-development Partner · 6 July 2021Partnership for test batch manufacturing of Sputnik V COVID-19 vaccine in India at Himachal Pradesh facility. Technology transfer underway with RDIF.

Scale indicators12 records

Recent moves7 records

Expansion highlights7 records

Broad incumbents

• Sun Pharmaceutical Industries: Largest Indian pharma with extensive API, generics and specialty portfolio. A larger incumbent operating across all of Morepen's segments; not a pure peer but provides the upper bound on Indian pharma scale and competitive pressure.

Direct peers

• Cipla Limited: Major Indian pharma with large OTC and domestic formulations presence alongside global API and generics. Comparable India consumer health channel and bulk drug positioning.
• Laurus Labs: Indian API and CDMO manufacturer focused on anti-retroviral, cardiovascular and oncology APIs with strong USFDA compliance. Comparable scale and business mix in API + contract manufacturing.
• Glenmark Pharmaceuticals: Indian pharma with API manufacturing, generics and specialty formulations. Comparable CDMO activity and emerging markets distribution.
• Lupin Limited: Indian generic pharma with substantial API manufacturing, USFDA-approved plants, and global exports. Comparable regulatory compliance, US generics exposure, and India formulations business.
• Dr. Reddy's Laboratories: Indian pharmaceutical major with API manufacturing, generic formulations, and OTC presence across India and global markets. Comparable in CDMO activity, USFDA-compliant manufacturing, and integrated business model.
• Zydus Lifesciences (Cadila Healthcare): Indian pharma with API, formulations, CDMO and consumer health businesses. Overlapping product categories in cardiac, diabetes and OTC consumer health.
• Torrent Pharmaceuticals: Indian pharma with focus on cardiac, diabetes and CNS generics plus API manufacturing. Comparable therapeutic area focus and chronic-disease franchise emphasis.
• Aurobindo Pharma: Large Indian generic pharma and API manufacturer with USFDA-approved facilities, similar product mix spanning APIs, formulations, and exports to regulated markets. Directly comparable in scale, regulatory positioning, and customer overlap.
• Divis Laboratories: India-headquartered pure-play API and custom synthesis (CDMO) specialist with strong USFDA track record. Most directly comparable to Morepen's API and CDMO businesses given technology and customer overlap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/dr_morepen
• YouTubeyoutube.com/@MorepenLabs
• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/morepen-laboratories-limited-india/?originalSubdomain=in
• Instagraminstagram.com/morepenofficial

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Morepen Laboratories